Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

Medicines that protect the kidneys

Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Until recently there were two kidney-protective treatments: control blood pressure and control blood sugar. Three new classes have changed that in about a decade.

They share a mechanism worth understanding, because it explains the thing that frightens people most about starting them: the eGFR goes down before it does better.

Related pages: Chronic kidney disease

The bottom line

What we know
  • ACE inhibitors and ARBs slow progression where albumin is leaking.
  • SGLT2 inhibitors slow progression in CKD with and without diabetes.
  • Finerenone reduces progression in CKD with type 2 diabetes.
  • An initial eGFR drop of up to about 30 percent after starting these is expected and not harmful.
  • Potassium and kidney function are checked after starting or increasing these drugs.
What is still open
  • The best order and combination of the three classes.
  • How much benefit people with very advanced CKD still obtain.
  • Long-term outcomes of combining all of them.

The story, step by step

  1. 1. ACE inhibitors and ARBs ()
  2. 2. SGLT2 inhibitors ()
  3. 3. Finerenone and the rest ()
  4. 4. The initial dip ()
  5. 5. Monitoring ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

The long-standing foundation

Review of many studies

What happens

They lower pressure inside the filter.

What the research shows

  • These drugs block the renin-angiotensin system, which both raises blood pressure and constricts the vessel leaving the glomerulus.
  • Blocking it dilates that vessel, lowering pressure inside the glomerulus specifically. That is why they reduce protein leak beyond what their blood pressure effect alone would explain.
  • They are recommended where albumin is leaking, in diabetic and non-diabetic CKD, and titrated to the highest tolerated dose.
  • An ACE inhibitor and an ARB are not combined. The combination raises harm without added benefit.
  • Potassium and creatinine are checked within a few weeks of starting or increasing the dose.
  • They are stopped in pregnancy, and anyone who might become pregnant should discuss this before starting. A dry cough is common with ACE inhibitors and usually resolves on switching to an ARB.

Why it matters

Reducing protein leak is a treatment goal in its own right, and these are the drugs that do it most directly.

What's still uncertain

  • The best target dose when blood pressure is already low.
  • Whether to continue them in very advanced CKD.

Read more

Next: SGLT2 inhibitors

Part 2 of 5

The change of the last decade

Review of many studies

What happens

Developed for diabetes, kept for kidneys.

What the research shows

  • These drugs block glucose reabsorption in the kidney tubule, so glucose leaves in the urine.
  • That changes the sodium signal reaching a sensor at the start of the tubule, which tightens the vessel entering the glomerulus and reduces hyperfiltration.
  • Large trials found reduced progression to kidney failure and reduced cardiovascular events in people with CKD, including those without diabetes.
  • They are now recommended for many people with CKD and albuminuria regardless of diabetes status, usually alongside an ACE inhibitor or ARB.
  • Common side effects are genital yeast infections and, less often, urinary infections. Good hygiene reduces the first substantially.
  • They are held during serious illness, prolonged fasting or before surgery, because of a small risk of ketoacidosis that can occur with near-normal blood sugar.

Why it matters

This is the first genuinely new kidney-protective class in decades, and the benefit is not explained by blood sugar lowering.

What's still uncertain

  • How much benefit remains at very low eGFR.
  • How best to sequence with the other classes.

Read more

Next: Finerenone and the rest

Part 3 of 5

The newer additions

Review of many studies

What happens

Inflammation and fibrosis.

What the research shows

  • Finerenone blocks the mineralocorticoid receptor, through which aldosterone drives inflammation and scarring in the kidney.
  • In trials in CKD with type 2 diabetes it reduced progression and cardiovascular events on top of ACE inhibitor or ARB treatment.
  • Its main risk is raised potassium, so potassium is checked before starting and during treatment, and the dose depends on both eGFR and potassium.
  • GLP-1 receptor agonists, developed for diabetes and weight, have shown kidney benefits in trials and are increasingly used in this group.
  • Statins reduce cardiovascular events in CKD, which matters because heart disease, not kidney failure, is the most likely outcome.
  • Spironolactone, an older drug in the same family as finerenone, lowers blood pressure in resistant hypertension but raises potassium more.

Why it matters

Treatment of CKD now looks like treatment of heart failure: several drugs with different mechanisms, each adding a slice of benefit.

What's still uncertain

  • The additive benefit of combining all available classes.
  • Whether GLP-1 drugs will become standard in non-diabetic CKD.

Read more

Next: The initial dip

Part 4 of 5

Why the number goes down first

Review of many studies

What happens

Expected, and a sign it is working.

What the research shows

  • Starting an ACE inhibitor, ARB or SGLT2 inhibitor lowers pressure inside the glomerulus, which lowers the filtration rate immediately.
  • The result is a fall in eGFR over the first weeks, commonly up to around 30 percent, which then stabilises.
  • In trials, the long-term slope of eGFR decline is shallower in people who had that initial dip. The acute change is the mechanism of the long-term benefit.
  • A drop beyond about 30 percent, or one that keeps falling, is investigated, since it may indicate dehydration, an interacting drug or renal artery disease.
  • Stopping the drug because of the expected dip is a common and costly error, and the number usually recovers when it is stopped, which makes the error look justified.
  • Clinicians plan the follow-up blood test specifically for this, usually two to four weeks after starting.

Why it matters

Of everything in CKD care, this is the point most worth understanding before starting treatment. It prevents people abandoning the drugs that work.

What's still uncertain

  • The exact threshold at which the drop should prompt stopping.
  • How to communicate this reliably at the point of prescribing.

Read more

Next: Monitoring

Part 5 of 5

What gets checked and when

Review of many studies

What happens

Mostly potassium and creatinine.

What the research shows

  • Blood tests two to four weeks after starting or changing the dose of an ACE inhibitor, ARB or finerenone.
  • Potassium matters because these drugs raise it, and high potassium can cause dangerous heart rhythms.
  • Mild rises are often managed with dietary change or a potassium binder rather than stopping an effective drug.
  • Blood pressure, urine albumin and eGFR are then followed at an interval set by risk category.
  • During any illness with vomiting, diarrhoea or fever, several of these drugs are temporarily held. Ask for written sick-day rules and keep them somewhere findable.
  • Anyone taking these should tell every clinician and pharmacist they have CKD, because many other drugs need dose adjustment.

Why it matters

The monitoring is what makes aggressive treatment safe. It is also what allows a mildly raised potassium to be managed rather than used as a reason to stop.

What's still uncertain

  • The best strategy for managing hyperkalemia without stopping treatment.
  • Optimal monitoring intervals by risk category.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.